NCT05998135View on ClinicalTrials.gov

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

November 9, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
Ovarian High Grade Serous AdenocarcinomaPlatinum-Resistant Ovarian Carcinoma
Interventions
DRUG

Atovaquone

Given PO

PROCEDURE

Biopsy

Undergo biopsy

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Paracentesis

Undergo paracentesis

Trial Locations (1)

30322

RECRUITING

Emory University Hospital/Winship Cancer Institute, Atlanta

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER